vs
Side-by-side financial comparison of InspireMD, Inc. (NSPR) and Token Cat Ltd (TC). Click either name above to swap in a different company.
InspireMD, Inc. is the larger business by last-quarter revenue ($3.1M vs $2.8M, roughly 1.1× Token Cat Ltd). On growth, InspireMD, Inc. posted the faster year-over-year revenue change (61.6% vs -37.9%).
InspireMD Inc. is a global medical device company specializing in innovative interventional cardiology and neurovascular solutions. Its flagship MGuard embolic protection stent line is engineered to reduce complications during vascular procedures, serving clinical customers across North America, Europe, and key Asia-Pacific markets, with a core focus on improving patient outcomes for acute coronary syndrome and stroke care.
NSPR vs TC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.1M | $2.8M |
| Net Profit | — | $-93.0K |
| Gross Margin | 37.5% | 79.0% |
| Operating Margin | -383.7% | -206.9% |
| Net Margin | — | -3.4% |
| Revenue YoY | 61.6% | -37.9% |
| Net Profit YoY | — | 98.3% |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.1M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $1.8M | $2.8M | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $1.9M | — | ||
| Q3 24 | $1.8M | — | ||
| Q2 24 | $1.7M | $4.4M | ||
| Q1 24 | $1.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-12.7M | — | ||
| Q2 25 | $-13.2M | $-93.0K | ||
| Q1 25 | $-11.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.9M | — | ||
| Q2 24 | $-7.9M | $-5.6M | ||
| Q1 24 | $-7.0M | — |
| Q4 25 | 37.5% | — | ||
| Q3 25 | 34.2% | — | ||
| Q2 25 | 17.6% | 79.0% | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 24.1% | — | ||
| Q3 24 | 22.9% | — | ||
| Q2 24 | 19.0% | 69.2% | ||
| Q1 24 | 19.3% | — |
| Q4 25 | -383.7% | — | ||
| Q3 25 | -517.3% | — | ||
| Q2 25 | -732.2% | -206.9% | ||
| Q1 25 | -749.5% | — | ||
| Q4 24 | -480.6% | — | ||
| Q3 24 | -467.5% | — | ||
| Q2 24 | -475.0% | -146.9% | ||
| Q1 24 | -490.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | -503.7% | — | ||
| Q2 25 | -739.7% | -3.4% | ||
| Q1 25 | -730.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -435.9% | — | ||
| Q2 24 | -454.8% | -125.9% | ||
| Q1 24 | -465.4% | — |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.17 | — | ||
| Q2 25 | $-0.26 | — | ||
| Q1 25 | $-0.22 | — | ||
| Q4 24 | $-0.17 | — | ||
| Q3 24 | $-0.16 | — | ||
| Q2 24 | $-0.22 | — | ||
| Q1 24 | $-0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $54.2M | $150.0K |
| Total DebtLower is stronger | — | $1.4M |
| Stockholders' EquityBook value | $55.2M | $4.6M |
| Total Assets | $69.4M | $28.4M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.2M | — | ||
| Q3 25 | $63.4M | — | ||
| Q2 25 | $19.4M | $150.0K | ||
| Q1 25 | $26.1M | — | ||
| Q4 24 | $34.6M | — | ||
| Q3 24 | $40.4M | — | ||
| Q2 24 | $47.2M | $689.0K | ||
| Q1 24 | $34.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | — |
| Q4 25 | $55.2M | — | ||
| Q3 25 | $64.1M | — | ||
| Q2 25 | $20.2M | $4.6M | ||
| Q1 25 | $28.3M | — | ||
| Q4 24 | $36.1M | — | ||
| Q3 24 | $41.4M | — | ||
| Q2 24 | $46.8M | $-787.0K | ||
| Q1 24 | $35.1M | — |
| Q4 25 | $69.4M | — | ||
| Q3 25 | $78.5M | — | ||
| Q2 25 | $33.3M | $28.4M | ||
| Q1 25 | $38.7M | — | ||
| Q4 24 | $46.8M | — | ||
| Q3 24 | $50.5M | — | ||
| Q2 24 | $55.7M | $12.5M | ||
| Q1 24 | $42.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.3M | $-23.7M |
| Free Cash FlowOCF − Capex | $-9.7M | — |
| FCF MarginFCF / Revenue | -309.4% | — |
| Capex IntensityCapex / Revenue | 12.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-36.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.3M | — | ||
| Q3 25 | $-8.6M | — | ||
| Q2 25 | $-8.3M | $-23.7M | ||
| Q1 25 | $-8.8M | — | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | $-5.7M | — | ||
| Q2 24 | $-4.4M | $-1.5M | ||
| Q1 24 | $-5.1M | — |
| Q4 25 | $-9.7M | — | ||
| Q3 25 | $-9.0M | — | ||
| Q2 25 | $-8.9M | — | ||
| Q1 25 | $-9.2M | — | ||
| Q4 24 | $-7.1M | — | ||
| Q3 24 | $-6.1M | — | ||
| Q2 24 | $-4.8M | $-1.5M | ||
| Q1 24 | $-5.3M | — |
| Q4 25 | -309.4% | — | ||
| Q3 25 | -355.2% | — | ||
| Q2 25 | -501.1% | — | ||
| Q1 25 | -598.5% | — | ||
| Q4 24 | -362.3% | — | ||
| Q3 24 | -338.2% | — | ||
| Q2 24 | -277.7% | -34.4% | ||
| Q1 24 | -348.0% | — |
| Q4 25 | 12.6% | — | ||
| Q3 25 | 13.0% | — | ||
| Q2 25 | 32.4% | — | ||
| Q1 25 | 23.5% | — | ||
| Q4 24 | 16.0% | — | ||
| Q3 24 | 23.3% | — | ||
| Q2 24 | 27.3% | 0.0% | ||
| Q1 24 | 12.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NSPR
| Other | $1.7M | 55% |
| US | $1.4M | 45% |
TC
Segment breakdown not available.
